Cochrane · systematic review · CD011735
Selective serotonin reuptake inhibitors for fibromyalgia syndrome
Walitt, B, Urrútia, G, Nishishinya, MB, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 7 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: Patients with fibromyalgia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of patients with at least 30% pain reduction | RD 0.1 [0.01, 0.2] | 6 studies · 343 participants | Very low |
Number of patients with a clinically important global improvement | RD 0.14 [0.06, 0.23] | 6 studies · 330 participants | Very low |
Fatigue (lower scores mean less fatigue) | no estimate extracted | 5 studies · 192 participants | Very low |
Sleep problems (lower scores mean less sleep problems) | no estimate extracted | 5 studies · 193 participants | Very low |
Depression (lower scores mean less depression) | no estimate extracted | 6 studies · 244 participants | Very low |
Discontinuation due to adverse events | RD 0.04 | 5 studies · 284 participants | Very low Downgraded: inconsistency |
Serious adverse events | no estimate extracted | 2 studies · 168 participants | Very low |